Promis Neurosciences (PMN) Competitors $0.48 +0.02 (+3.92%) Closing price 04:00 PM EasternExtended Trading$0.48 0.00 (-0.21%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN vs. SPRO, ABOS, SCLX, TCRX, ZNTL, CGTX, EXOZ, ALXO, MGNX, and ADVMShould you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include Spero Therapeutics (SPRO), Acumen Pharmaceuticals (ABOS), Scilex (SCLX), TScan Therapeutics (TCRX), Zentalis Pharmaceuticals (ZNTL), Cognition Therapeutics (CGTX), eXoZymes (EXOZ), ALX Oncology (ALXO), MacroGenics (MGNX), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry. Promis Neurosciences vs. Its Competitors Spero Therapeutics Acumen Pharmaceuticals Scilex TScan Therapeutics Zentalis Pharmaceuticals Cognition Therapeutics eXoZymes ALX Oncology MacroGenics Adverum Biotechnologies Spero Therapeutics (NASDAQ:SPRO) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership. Do institutionals and insiders have more ownership in SPRO or PMN? 25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 5.5% of Spero Therapeutics shares are held by insiders. Comparatively, 3.8% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, SPRO or PMN? Promis Neurosciences has lower revenue, but higher earnings than Spero Therapeutics. Spero Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$47.98M2.92-$68.57M-$0.98-2.54Promis NeurosciencesN/AN/A$2.78M-$0.21-2.27 Does the media refer more to SPRO or PMN? In the previous week, Spero Therapeutics had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 6 mentions for Spero Therapeutics and 4 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.74 beat Spero Therapeutics' score of 0.42 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SPRO or PMN? Spero Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500. Is SPRO or PMN more profitable? Promis Neurosciences has a net margin of 0.00% compared to Spero Therapeutics' net margin of -110.35%. Spero Therapeutics' return on equity of -120.27% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics-110.35% -120.27% -55.61% Promis Neurosciences N/A -266.69%-131.59% Do analysts prefer SPRO or PMN? Spero Therapeutics presently has a consensus target price of $5.00, suggesting a potential upside of 100.80%. Promis Neurosciences has a consensus target price of $4.33, suggesting a potential upside of 808.46%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, analysts clearly believe Promis Neurosciences is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Promis Neurosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryPromis Neurosciences beats Spero Therapeutics on 9 of the 15 factors compared between the two stocks. Get Promis Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.70M$3.37B$6.11B$10.46BDividend YieldN/A2.29%5.73%4.77%P/E Ratio-2.2722.7785.3627.36Price / SalesN/A485.21607.16135.99Price / CashN/A46.7037.4661.86Price / Book0.9510.5512.426.81Net Income$2.78M-$52.58M$3.32B$276.80M7 Day Performance-16.26%1.09%1.01%0.27%1 Month Performance14.01%16.09%10.75%8.31%1 Year Performance-54.13%18.41%76.20%35.60% Promis Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNPromis Neurosciences3.3321 of 5 stars$0.48+3.9%$4.33+808.5%-54.1%$24.70MN/A-2.275Gap UpSPROSpero Therapeutics4.2787 of 5 stars$2.16+3.3%$5.00+131.5%+91.9%$117.61M$47.98M-2.20150News CoverageAnalyst DowngradeHigh Trading VolumeABOSAcumen Pharmaceuticals3.2475 of 5 stars$1.88-3.1%$7.00+272.3%-0.9%$117.51MN/A-0.8220News CoverageAnalyst ForecastSCLXScilex2.2368 of 5 stars$18.23+8.4%$455.00+2,395.9%-47.1%$117M$56.59M-0.6380TCRXTScan Therapeutics2.6186 of 5 stars$1.97-3.9%$7.80+295.9%-62.0%$116.33M$2.82M-1.81100ZNTLZentalis Pharmaceuticals1.7286 of 5 stars$1.55-2.5%$5.84+276.8%-48.0%$114.69M$67.43M-0.69160CGTXCognition Therapeutics2.594 of 5 stars$1.75+13.6%$2.83+61.9%+308.1%$113.23MN/A-2.6120EXOZeXoZymes0.9098 of 5 stars$13.50+1.5%N/AN/A$113.23M$70K0.0029ALXOALX Oncology3.9673 of 5 stars$1.83-13.3%$3.30+80.3%+9.7%$112.99MN/A-0.8340Gap UpMGNXMacroGenics4.4275 of 5 stars$1.72-2.3%$3.60+109.3%-62.4%$111.24M$149.96M-3.02430ADVMAdverum Biotechnologies3.7963 of 5 stars$4.94-6.8%$19.75+299.8%-40.6%$111.22M$1M-0.63190 Related Companies and Tools Related Companies Spero Therapeutics Alternatives Acumen Pharmaceuticals Alternatives Scilex Alternatives TScan Therapeutics Alternatives Zentalis Pharmaceuticals Alternatives Cognition Therapeutics Alternatives eXoZymes Alternatives ALX Oncology Alternatives MacroGenics Alternatives Adverum Biotechnologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMN) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
